Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ADP-ribose pyrophosphatase, mitochondrial (NUDT9) is a monomeric enzyme of the Nudix hydrolase family, functioning primarily in the mitochondria. It catalyzes the hydrolysis of ADP-ribose to AMP and ribose 5-phosphate, requiring divalent metal ions and an intact Nudix motif. NUDT9 exhibits remarkable substrate specificity for ADP-ribose and is critical for regulating intracellular levels of this molecule, maintaining cellular metabolic balance, and protecting cells from toxicity due to accumulation of nucleotide derivatives. Additionally, NUDT9’s activity impacts the gating of the TRPM2 channel, linking it to Ca²⁺-dependent apoptotic signaling. Alternative splicing generates mitochondrial (alpha) and non-mitochondrial (beta) isoforms, distributed in tissues including heart, skeletal muscle, liver, kidney, and pancreas.
Substrate-mimetic inhibition of ADP-ribose hydrolysis (potential mechanism of candidate inhibitors). Indirect modulation of TRPM2 channel activity by altering ADPR levels.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ADP-ribose pyrophosphatase, mitochondrial (NUDT9).